Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Other Non-Current Assets (2019 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Other Non-Current Assets for 7 consecutive years, with $9.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets rose 227.51% to $9.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $9.4 million, a 227.51% increase, with the full-year FY2024 number at $4.3 million, up 522.95% from a year prior.
  • Other Non-Current Assets was $9.4 million for Q3 2025 at 4D Molecular Therapeutics, roughly flat from $9.4 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $9.4 million in Q2 2025 to a low of $602000.0 in Q1 2021.
  • A 5-year average of $2.4 million and a median of $1.1 million in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: crashed 38.81% in 2024, then soared 813.49% in 2025.
  • 4D Molecular Therapeutics' Other Non-Current Assets stood at $602000.0 in 2021, then soared by 79.4% to $1.1 million in 2022, then tumbled by 36.67% to $684000.0 in 2023, then soared by 522.95% to $4.3 million in 2024, then soared by 120.14% to $9.4 million in 2025.
  • Per Business Quant, the three most recent readings for FDMT's Other Non-Current Assets are $9.4 million (Q3 2025), $9.4 million (Q2 2025), and $7.0 million (Q1 2025).